Top Markets
#1 EXOD EXOD +22.08%
#2 Status Status +18.25%
#3 Ontology Gas Ontology Gas +14.98%
#4 Derive Derive +11.23%
#5 Fake World Assets Fake World Assets +9.05%
#6 aelf aelf +8.29%
#7 Anvil Anvil +5.72%
#8 Tornado Cash Tornado Cash +5.44%
#9 The Black Bull The Black Bull +5.21%
#10 B3 (Base) B3 (Base) +5.04%
Coin of the day
EXOD EXOD
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Recro Pharma, Inc. Recro Pharma, Inc.

Recro Pharma, Inc.

REPH
Rang in aandelen #25706
Recro Pharma, Inc. operates as a contract development and manufacturing... Recro Pharma, Inc. operates as a contract development and manufacturing organization (CDMO), offering comprehensive services for the development, production, and packaging of diverse therapeutic dosage forms. The company primarily specializes in small molecule therapeutic development, serving both domestic U.S. and international clients. Its extensive capabilities encompass a wide array of formats, including oral solid doses, sterile injectable solutions, oral liquid preparations, tablets, topical formulations, liquid/powder-filled capsules, ophthalmic droppers, liposomal products, and nano/microparticles. Furthermore, Recro Pharma provides specialized services such as aseptic fill/finish, lyophilization (freeze-drying), final packaging, and logistics management. Originally founded as Recro Pharma I, Inc., the company underwent a name change to Recro Pharma, Inc. in August 2008. The organization was established in 2007 and is headquartered in Exton, Pennsylvania.
Aandeelprijs
$2.09
Laatst gesynchroniseerd: 2022-03-21
Marktkapitalisatie
$47.04M
Verandering (1 dag)
-0.48%
Verandering (1 jaar)
0.00%
Land
US
Handel Recro Pharma, Inc. (REPH)

Categorie

Healthcare
Winst voor Recro Pharma, Inc. (REPH)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Recro Pharma, Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Recro Pharma, Inc. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
- -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
- -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
- -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
- -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
$1.76B -
IN